a2) United States Patent
`US 9,758,784 B1
`(0) Patent No.:
`*Sep. 12, 2017
`(45) Date of Patent:
`Giese et al.
`
`US009758784B1
`
`(54)
`
`INTERFERING RNA MOLECULES
`
`(71) Applicant: Silence Therapeutics GMBH,Berlin
`(DE)
`
`(72)
`
`Inventors: Klaus Giese, Berlin (DE); Jorg
`Kaufmann, Berlin (DE); Anke
`Klippel-Giese, Berchtesgaden (DE)
`
`(73) Assignee: Silence Therapeutics GMBH,Berlin
`(DE)
`
`(*) Notice:
`
`Subject to any disclaimer, the term ofthis
`patent is extended or adjusted under 35
`U.S.C. 154(b) by 0 days.
`
`This patent is subject to a terminal dis-
`claimer.
`
`(21) Appl. No.: 15/589,971
`
`(22)
`
`Filed:
`
`May8, 2017
`
`Related U.S. Application Data
`
`(63) Continuation of application No. 14/977,710, filed on
`Dec. 22, 2015, which is a continuation of application
`No. 14/578,636, filed on Dec. 22, 2014, now Pat. No.
`9,222,092, which is a continuation of application No.
`13/692,178, filed on Dec. 3, 2012, now Pat. No.
`8,933,215, which is a continuation of application No.
`12/986,389,
`filed on Jan. 7, 2011, now Pat. No.
`8,324,370, which is a continuation of application No.
`12/200,296, filed on Aug. 28, 2008, now Pat. No.
`7,893,245, which is a continuation of application No.
`10/633,630, filed on Aug. 5, 2003, now Pat. No.
`7,452,987.
`
`(60) Provisional application No. 60/402,541, filed on Aug.
`12, 2002.
`
`(30)
`
`Foreign Application Priority Data
`
`Aug. 5, 2002
`Apr. 10, 2003)
`
`(EP) wee ceeeeteeecrseeneeeees 02017601
`(EP) we ceeeeeeeenenecenees 03008383
`
`(51)
`
`(2006.01)
`(2010.01)
`
`Int. Cl.
`CO7H 21/04
`CI2N 15/113
`(52) U.S. Cl.
`CPC ........ CI2N 15/113 (2013.01); CI2N 15/1137
`(2013.01); C12Y 207/11001 (2013.01); C12N
`2310/14 (2013.01); C12N 2310/32] (2013.01);
`C1I2N 2310/322 (2013.01); C12N 2310/531
`(2013.01); C12N 2320/51 (2013.01)
`(58) Field of Classification Search
`None
`
`See application file for complete search history.
`
`(56)
`
`References Cited
`U.S. PATENT DOCUMENTS
`
`4,217,294 A
`5,466,786 A
`5,514,546 A
`
`8/1980 Petty
`11/1995 Buhret al.
`5/1996 Kool
`
`12/1996 Pageset al.
`5,589,389 A
`9/1997 Cooketal.
`5,670,633 A
`8/1998 Buhr etal.
`5,792,847 A
`2/1999 Cooketal.
`5,872,232 A
`4/1999 Crooke
`5,898,031 A
`6/1999 Cooketal.
`5,914,396 A
`9/1999 Cooketal.
`5,955,589 A
`12/1999 Cook et al.
`6,005,087 A
`8/2000 Crooke
`6,107,094 A
`10/2000 Hortin et al.
`6,129,912 A
`6,133,246 A * 10/2000 McKay ou... C07H 21/00
`435/183
`
`6,153,737 A
`6,165,772 A
`6,239,272 Bl
`6,262,036 B1*
`
`11/2000 Manoharan etal.
`12/2000 Bertling
`5/2001 Beigelman et al.
`7/2001 Arnold, Jr.
`......... C12N 15/1131
`435/6.14
`
`6,284,267 Bl
`6,476,205 Bl
`6,506,559 BI
`6,531,584 Bl
`6,617,438 Bl
`6,812,204 Bl
`7,056,704 B2
`7,074,863 B2
`7,078,196 B2
`7,138,517 B2
`7,148,342 B2
`7,196,184 B2
`7,348,314 B2
`
`9/2001 Aneja
`11/2002 Buhr etal.
`1/2003 Driveretal.
`3/2003 Cooketal.
`9/2003 Beiqelman etal.
`11/2004 McHaleetal.
`6/2006 Tuschlet al.
`7/2006 Ekholm et al.
`7/2006 Tuschlet al.
`11/2006 Cooketal.
`12/2006 Tolentino et al.
`3/2007 Heidenreich etal.
`3/2008 John etal.
`(Continued)
`
`FOREIGN PATENT DOCUMENTS
`
`CA
`DE
`
`2476112 Al
`19618797 Al
`
`8/2003
`11/1997
`
`(Continued)
`
`OTHER PUBLICATIONS
`
`U.S. Appl. No. 60/352,873, filed Feb. 1, 2002, Damhaetal.
`U.S. Appl. No. 60/358,580, filed Feb. 20, 2002, Beiqelman etal.
`U.S. Appl. No. 60/363,124, filed Mar. 11, 2002, Beigelman etal.
`U.S. Appl. No. 60/386,782, filed Jun. 6, 2002, Beigelman et al.
`Amarzguioui, M. et al. “Tolerance for mutations and chemical
`modifications in a siRNA”, Nucleic Acids Research, 2003, pp.
`589-595, vol. 31, No. 2.
`Andrew Fire. et al., Potent and specific genetic interference by
`double-stranded RNA in Caenorhabditis elegans, Nature Macmilian
`Publishers Ltd. 1993, vol. 391/191, pp. 806-811.
`(Continued)
`
`Primary Examiner — Kimberly Chong
`(74) Attorney, Agent, or Firm — Morrison & Foers
`LLP
`
`(57)
`
`ABSTRACT
`
`The present invention is related to a ribonucleic acid com-
`prising a double stranded structure whereby the double-
`stranded structure comprises a first strand and a second
`strand, whereby the first strand comprises a first stretch of
`contiguous nucleotides and whereby said first stretch is at
`least partially complementary to a target nucleic acid, and
`the second strand comprises a secondstretch of contiguous
`nucleotides whereby said secondstretch is at least partially
`identical to a target nucleic acid, and whereby the double
`stranded structure is blunt ended.
`
`24 Claims, 29 Drawing Sheets
`
`Alynlam Exh. 1001
`
`Alynlam Exh. 1001
`
`

`

`US 9,758,784 B1
`Page 2
`
`4/2004
`WO-2004/035615 A2
`WO
`(56)
`1/2005
`WO-2005/000320 A2
`WO
`
`WO WO-2005/105152 A2—11/2005
`U.S. PATENT DOCUMENTS
`WO
`WO-2006/023544 A2
`3/2006
`WO
`WO-2006/069782 A2
`7/2006
`WO
`WO-2007/048244 A2
`5/2007
`WO
`WO-2007/084684 A2
`7/2007
`
`References Cited
`
`2/2003
`2003/0027783 Al
`Zernicka-Goetz etal.
`6/2003
`2003/0108923 Al
`Tuschl etal.
`7/2003
`2003/0135033 Al
`Klippel-Giese et al.
`10/2003
`2003/0190635 Al
`McSwiggen
`3/2004
`2004/0053875 Al
`Kreutzer et al.
`OTHER PUBLICATIONS
`4/2004
`2004/0072779 Al
`Kreutzer et al.
`5/2004
`2004/0102408 Al
`Kreutzer et al.
`Andrew J. Hamilton and David C. Balcombe, Species of Small
`6/2004
`2004/0106569 Al
`Antisense RNAin Posttranscriptional Gene Silencing in Plants, SCI
`Klippel-Giese et al.
`9/2004
`2004/0175703 Al
`Kreutzer et al.
`ENCE, vol. 286. Dec. 1999, pp. 950-951.
`9/2004
`2004/0180351 Al
`Giese et al.
`Antonio Regalado, Turning Off Genes Sheds New Light on How
`11/2004
`2004/0229266 Al
`Tuschl etal.
`They Work, The Wall Street Journal, Aug. 2002.
`2/2005
`2005/0043263 Al
`Giese et al.
`Antti Nykanen et al., “ATP Requirements and Small Interfering
`5/2005
`2005/0100907 Al
`Kreutzer et al.
`RNAStructure in the RNA Interference Pathway”, Cell, Nov. 2,
`6/2005
`2005/0142535 Al
`Damhaetal.
`2001, pp. 309-321, vol. 107.
`5/2006
`2006/0094678 Al
`Vornlocheretal.
`Applicant’s Response to the Written Opinion in the Examination
`6/2006
`2006/0142226 Al
`Polisky et al.
`proceedings Mar. 28, 2001.
`9/2006
`2006/0217329 Al
`Feinstein
`Barawkar, D.A. et al., Synthesis, Biophysical Properties, and.
`10/2006
`2006/0240022 Al
`Klippel-Giese et al.
`2/2007
`2007/0027097 Al
`Lewis
`Nuclease
`Resistance
`Properties
`of Mixed
`Backbone
`4/2007
`2007/0093445 Al
`Tuschl etal.
`Oligodeoxynucleotides Containing Cationic
`Internucleoside
`6/2007
`2007/0135372 Al
`MacLachlan et al.
`Guanidinium Linkages: Deoxynucleic Guanidine DNA Chimeras,
`
` Rossi etal.2007/0265220 Al=11/2007
`Proc. R165 Natl. Acad. Sci. USA, vol. 95, pp. 1104 7-11052, Sep.
`Kreutzer et al.
`2014/0220676 Al
`8/2014
`1998 Chemistry, Biochemistry.
`Barber, GN et al., Mol. and Cell. Biol. (1995), vol. 15, No. 6, p.
`3138-46.
`Behlke, M.A. (Dec. 2008). “Chemical modification of siRNAs for
`in vivo use,” Oligonucleotides 18(4):305-320.
`Bertrand, J. et al. “Comparison of antisense oligonucleotides and.
`siRNAsin cell culture and in vivo”, Biochemical and Biophysical
`Research Communications, 2002, pp. 1000-1004, vol. 296.
`Bevilacqua and Cech; “Minor-Groove Recognition of Double-
`Stranded RNA by the Double-Stranded RNA-Binding;” Biochem-
`istry 1996, 35, pp. 9983-9994.
`Bhan et al., Nucleic Acid Research, vol. 25, 1997, p. 3310.
`Billy, E. et al. “Specific interference with gene expression induced.
`by long, doublestranded RNA in mouse embryonal teratocarcinoma
`cell lines”, PNAS, Dec. 4, 2001, pp. 14428-14433, vol. 98, No. 25.
`Borecky L, et al., Therapeutic Use of Double-Stranded RNAsin
`man, Tex Rep Bio Med 1981-1982, vol. 41, pp. 575-581.
`Boutla, A et al. “Short 5'-phosphorylated double-stranded RNAs
`induce RNAinterference in Drosophila”, Current Biology, Nov. 13,
`2001, pp. 1776-1780, vol. 11.
`Braasch, DA et al. “RNA Interference in Mammalian Cells by
`Chemically-Modified RNA”, Biochemistry, 2003, pp. 7967-7975,
`vol. 42.
`Brennicke et al., FEMS Microbiol. Rev., vol. 23, p. 297-316 1999.
`Brief Communication (Interlocutory decision) in EPO Patent No. 1
`527 176 (EP 03 784183.0) dated Mar. 15, 2010, pp. 1-75.
`Brown, K. M. et al. “Target accessibility dictates the potency of
`human RISC”, Nature Structural & Molecular Biology, May 2005,
`pp. 469-470, vol. 12, No. 5.
`Byrom, MW., et al., TechNotes 10(1), Ambion,http://www.ambion.
`com, Mar. 2003.
`Caplen et al; “Specific inhibition of gene expression by small
`double-stranded RNAsin invertebrate and vertebrate systems” Proc
`Natl Acad Sci U SA. Aug. 14, 2001;98(17):9742-7.
`Chien, et al., Cancer Gene Therapy, 1-8, 2004.
`Chiu et al. “siRNA function in RNAi: a chemical modification
`analysis.’"RNA. 2003 ep;9(9): 1034-48.
`Chiu, Y. et al. “RNAi
`in Human Cells: Basic Structural and
`Functional Features of Small Interfering RNA”, Molecular Cell,
`Sep. 2002, pp. 549-561, vol. 10.
`Chiu, Y. et al. (Sep. 2003). “siRNA function in RNAi: A chemical
`modification analysis” RNA 9 (9):1034-1048.
`Chounget al “Chemical modification of siRNAs to improve serum
`stability without loss of efficacy.” Biochem Biophys Res Commun.,
`Apr. 14, 2006;342(3):919-27.
`Christian Cazenave et al., “Rate of degradation of [a]- and LB]-
`oligodeoxynucleotides in Xenopus oocytes. implications for anti-
`messenger strategies”, Nucleic Acids Research, 1987, DD. 10507-
`10521, vol. 15, No. 24.
`
`19903713
`19956568 Al
`0586520 Bl
`0618925 Bl
`1214945 A2
`1144623 Bl
`020185724
`1230375 Bl
`1550719 Al
`1527176 Bl
`1798285 Al
`1407044 Bl
`992744 A
`2417727 B
`WO-92/07065 Al
`WO-92/19732 Al
`WO-92/20823 Al
`WO-93/13121 Al
`WO-94/01550 Al
`WO-95/13834 Al
`WO-96/18376 Al
`WO-96/18736 A2
`WO-97/41141 Al
`WO-97/46570 Al
`WO-98/05770 A2
`WO-98/53083 Al
`WO-99/15682 A2
`WO-99/32619 Al
`WO-99/49029 Al
`WO-99/53050 Al
`WO-99/55857 A2
`WO-99/61631 Al
`WO-00/01846 A2
`WO-00/44495 Al
`WO-00/44895 Al
`WO-00/44914 Al
`WO-00/63364 A2
`WO-01/36646 Al
`WO-01/75164 A2
`WO-02/16620 A2
`WO-02/44321 A2
`WO-02/055693 A2
`WO-02/097114 A2
`WO-03/064441 A2
`WO-03/070895 A2
`WO-03/070912 A2
`WO-03/070918 A2
`WO-2004/015107 A3
`WO-2004/019973 Al
`
`FOREIGN PATENT DOCUMENTS
`
`DE
`DE
`EP
`EP
`EP
`EP
`EP
`EP
`EP
`EP
`EP
`EP
`GB
`GB
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`
`1/1999
`8/2000
`4/2000
`8/2001
`6/2002
`8/2002
`8/2002
`7/2005
`7/2005
`1/2007
`6/2007
`9/2007
`5/1965
`1/2008
`4/1992
`11/1992
`11/1992
`TN993
`1/1994
`5/1995
`6/1996
`6/1996
`11/1997
`12/1997
`2/1998
`11/1998
`4/1999
`7/1999
`9/1999
`10/1999
`11/1999
`12/1999
`1/2000
`8/2000
`8/2000
`8/2000
`10/2000
`5/2001
`10/2001
`2/2002
`6/2002
`7/2002
`12/2002
`8/2003
`8/2003
`8/2003
`8/2003
`2/2004
`3/2004
`
`

`

`US 9,758,784 B1
`
`Page 3
`
`(56)
`
`References Cited
`OTHER PUBLICATIONS
`
`Clayton, J. “The Silent Treatment”, Nature, Sep. 30, 2004, pp.
`599-605, vol. 431.
`Clemens,J.C. et al. “Use of double-stranded RNA interference in
`Drosophilia cell
`lines to dissect signal transduction pathways”,
`PNAS,Jun. 6, 2000, pp. 6499-6503, vol. 97, No. 12.
`Clemens, M. J. “PKR—A Protein Kinase Regulated by Double-
`stranded RNA”, Int. J Biochem. Cell Biol., 1997, pp. 945-949, vol.
`29, No. 7.
`Collingwood MA (Jun. 2008). “Chemical modification patterns
`compatible with high potency dicer-substrate small
`interfering
`RNAs,” Olingonculeotides, 18(2)187-200.
`Comparative Figure: D10 (Pachuk) v. Opposed Patent, Feb. 2, 2007.
`Comparative Figure: D60 (Agrawal) v. Opposed Patent, Feb. 2,
`2007.
`Conklin, D., et al., “Association of nucleotide patterns with gene
`function classes: application to human 3’ untranslated sequences,”
`Bioinformatics, 2002, vol. 18, No. 1, pp. 182-189.
`Conrad et al. “Ribonuclease III: new sense from nuisance.” Int J
`Biochem Cell Biol. Feb. 2002; 34(2): 116-29.
`Crooke, R. M. et al. “Metabolism of Antisense Oligonucleotides in
`Rat Liver Homogenates”, The Journal of Pharmacology and Experi-
`mental Therapeutics, 2000, pp. 140-149, vol. 292.
`Czauderna,F.et al. “Functional Studies of the PI(3)-kinase signal-
`ing pathway employing synthetic and expressed siRNA”, Nucleic
`Acids Research, 2003, pp. 670-682, vol. 31, No. 2.
`David C. Baulcombe, “Fast forward genetics based on virus-
`induced gene silencing”, Current Opinion in Plant Biology, 1999,
`pp. 109-113, vol. 2.
`Declaration of Professor Dr. Michael Gait, filed Aug. 5, 2003,
`76pages.
`Delivery Note, 2 pages, Dec. 20, 2001.
`Doench,J. G. et al., siRNAs Can Function as miRNAs, Genes &
`Development, vol. 17, pp. 438-442, 2003.
`Dorsett, Y. et al. “siRNAs: Applications in Functional Genomics and
`Potential as Therapeutics”, Drug Discovery, Apr. 2004, pp. 318-329,
`vol. 3.
`Elayadi, A N. et al. “Application of PNA and LNA oligomers to
`chemotherapy” Current Opinion in Investigational Drugs, 2001, pp.
`558-561, vol. 2, No. 4.
`Elbashir SM,et al., Duplexes of 21-Nucleotide RNAs Mediate RNA
`Interference in Cultured Mammalian Cells, Nature, vol. 411, pp.
`494-498, May 2001.
`Elbashir, et al.. RNA Interference is Mediated by 21- and
`22-Nucleotide RNAs, Genes & Development vol. 15, pp. 188-200,
`Jan. 2001.
`Emily Bernstein et al., “Role for a bidentate ribonuclease in the
`initiation step of RNA interference”, Nature, Jan. 18, 2001, p.
`363-366, vol. 409.
`EPO Register extract for WO 03/070895, Dec. 9, 2007, pp. 1-2.
`EPO Register extract for WO 03/070918, Nov. 9, 2007, pp. 1-4.
`Eric Billy et al., “Specific Interference with Gene Expression
`Induced by Long, Double-Stranded RNA in Mouse Embryonal
`Teratocarcinoma Cell Lines”, Proceedings of the National Academy
`of Sciences of the United States of America, Dec. 4, 2001, pp.
`14428-14433, vol. 98, No. 25.
`Eric G. Moss, et al, The Cold Shock Domain Protein Lin-28
`Controls Developmental Timing in C. Elegans and is Regulated by
`the Lin-4 RNA,Cell, vol. 86, pp. 637-646, Mar. 7, 1997.
`Eric Wickstrom, “Oligodeoxynucleotide stability in subcellular
`extracts and culture media”, Journal of Biochemical and Biophysi-
`cal Methods, 1986, pp. 97-102, vol. 13.
`Eugen Uhlmann,et al.. Antisense Oligonucleotides: A New Thera-
`peutic Principle, vol. 90, No. 4, pp. 553-584, Jun. 1990.
`Extract from Hackh’s Chemical Dictionary, Fourth Edition, 1969,
`McGraw-Hill, p. 492.
`Extract from McGraw-Hill Dictionary of Scientific and Technical
`Terms, Fifth Edition, 2003, p. 1457.
`Extract from Shorter Oxford English Dictionary, 51th ed., 2003,
`relating to “pattern”, pp. 1-3.
`
`Fire, “RNA-triggered. gene Silencing:” TIG, pp. 358-363, vol. 15,
`No. 9, Sep. 1999.
`Florence Wianny,et al. Specific Interference with Gene Function by
`Double-Stranded RNA in Early Mouse Development, Nature Cell
`Biology, vol. 2, Feb. 2000, pp. 70-75.
`Frank Czauderna, et al., Structural Variations and Stabilising Modi-
`fications of Synthetic siRNAs in Mammalian Cells, Nucleic Acids
`Research, 2003, vol. 31, No. 11, pp. 2705-2716.
`Friedrich Lottspeich I Haralabos Zorbas: Bioanalytics, 1998, pp.
`785, 794.
`Gary, D. J. et al. “Polymer-based siRNA delivery: Perspectives on
`the fundamental and phenomenological distinctions from polymer-
`based DNA delivery”, Journal of Controlled Release, 2007, pp.
`64-73, vol. 121.
`Glenn D. Hoke et al., Effects of Phosphorothioate Capping on
`Antisense Oligonucleotide Stability, Hybridization and Antiviroal
`Efficacy Versus Herpes Simplex Virus Infection, Nucleic Acids
`Research, 1991, vol. 19, No. 20, pp. 5743-5748.
`Good,P. D. et al. “Expression of small, therapeutic RNAs in human
`cell nuclei” Gene Therapy, 1997, pp. 45-54, vol. 4.
`Grasby, J. A. et al., Purine Functional Groupsin Essential Residues
`of the Hairpin Ribozyme Required for Catalytic Cleavage of RNA,
`Biochemistry 1995, vol. 34, pp. 4068-4076.
`Griffey, R. H. et al., 2'-O-Aminoprophyl Ribonucleotides; A Zwit-
`terionic Modification that Enhances the Exonuclease Resistance and.
`Biological Activity of R156 Antisense Oligonucleotides, J. Med.
`Chem, 1996, vol. 39, pp. 5100-5109.
`Grounds of Appeal filed on behalf of Alcon Laboratories, Inc. in
`EPOPatent No. 1 527 176 (EP Patent Application No. 03. 784183.0)
`dated Jul. 26, 2010, pp. 1-63.
`Grunweller et al. “Comparison of different antisense strategies in
`mammalian cells using locked nucleic acids, 2'-O-methyl RNA,
`phosphorothioates and small interfering RNA” Nucleic Acids Res.
`Jun. 15, 2003;31(12):3185-93.
`Guan, K. L. et al. “Eukaryotic Proteins Expressed. in Escherichia
`coli: An Improved. Thrombin Cleavage and Purification Procedure
`of Fusion Proteins with Glutathione S-Transferase” Analytical Bio-
`chemistry, 1991, pp. 262-267, vol. 129.
`Hall,
`I. M.
`et
`al.
`“Establishment and Maintenance of a
`Heterochromatin Domain”, Science, Sep. 27, 2002, pp. 2232-2237,
`vol. 297.
`Hammond,S. M. et al. “Argonaute2, a Link Between Genetic and.
`Biochemical Analyses ofRNAi”, Science, Aug. 10, 2001, pp. 1146-
`1150, vol. 293.
`Hammond, S.M. et al. “An RNA-directed nuclease mediates post-
`transcriptional gene silencing in Drosophila cells”, Nature, Mar. 16,
`2000, pp. 293-296, vol. 404.
`Hannon, G. J. “RNA interference”, Nature, Jul. 11, 2002, pp.
`244-251, vol. 418.
`Harborth,et al.,“Identification of essential genes in cultured mam-
`malian cells using small interfering RNAs;” J Cell Science; 114: pp.
`4557-4565; (2001).
`Harborth,J. et al. “Sequence, Chemical, and Structural Variation of
`Small Interfering RNAs and Short Hairpin RNAsand the Effect on
`Mammalian Gene Silencing”, Antisense and Nucleic Acid Drug
`Development, 2003, pp. 83-105, vol. 13.
`Hoerter, J. A. et al. “Chemical Modification Resolves the Asym-
`metry of siRNA Strand Degradation in Human Blood Serum”,
`RNA,2007, pp. 1-7, vol. 13.
`Holen, T. et al. “Positional Effects of Short Interfering RNAs
`targeting the human coagulation trigger Tissue Factor’, Nucleic
`Acids Research, 2006, pp. 1757-1766, vol. 30, No. 8.
`Hornunget al., Nature Medicine, vol. 11, No. 3, pp. 263-270, Mar.
`2005.
`Hu, X. et al. “Relative gene-silencing efficiencies of small interfer-
`ing RNAstargeting sense and antisense transcripts from the same
`genetic locus”, Nucleic Acids Research, 2004, pp. 4609-4617, vol.
`32, No. 15.
`Hu-Lieskovan, et al, Cancer Res., vol. 65, No. 19, pp. 8984-8992,
`Oct. 1, 2005.
`Hunter, et al., JBC, vol. 250, No. 2, pp. 409-417, Jan. 25, 1975.
`
`

`

`US 9,758,784 B1
`
`Page 4
`
`(56)
`
`References Cited
`OTHER PUBLICATIONS
`
`liho Haet al., A Bulged Lin-4/1 in-14 RNA Duplexis Sufficient for
`Caenorhabditis Elegans Lin-14 Temporal Gradient Formation,
`Genes & Development, 1996, vol. 10, pp. 3041-3050.
`Ikuma Maedaet al., “Large-scale analysis of gene function in
`Caenorhabditis elegans by high-throughput RNAi”, Current Biol-
`ogy, 2001, pp. 171-176, vol. 11.
`Inoue et al.,“Synthesis and hybridization studies on two comple-
`mentary nona(2'0-methyl)ribonucleotides”; Nucleic Acids Res.,
`1987, pp. 6131-6148, vol. 15.
`Inoue,A.et al. “Molecular Design and Delivery of siRNA”, Journal
`of Drug Targeting, 2006, pp. 448-455, vol. 14, No. 7.
`International Preliminary Examination Report, (English Transla-
`tion) DE 0000244 (IPER), Jul. 7, 2003.
`Jackson, A. L. et al. “Position-specific chemical modification of
`siRNAs reduces “off-target” transcript silencing”, RNA, 2006, pp.
`1197-1205, vol. 12.
`Jason R. Kennerdellet al., “Heritable gene silencing in Drosophila
`using doublestranded RNA”, Nature Biotechnology, Jul. 2000, pp.
`896-898, vol. 17.
`Jason R. Kennerdell et al., “Use of dsRNA-Mediated Genetic
`Interference to Demonstrate that frizzled and frizzled 2 Act in the
`Wingless Pathway”, Cell, Dec. 23, 1998, pp. 1017-1026, vol. 95.
`Jason R. Kennerdell, et al. Use of dsRNA-Mediated Genetic Inter-
`ference to Demonstrate that Frizzled and Frizzled 2 Act in the
`Wingless Pathway, Cell, vol. 95, pp. 1017-1026, Dec. 23, 1998.
`Jennifer Couzin, Breakthrough, Small RNAs Make Big Splash,
`Science, vol. 298, pp. 2296-2297, Dec. 2002.
`John Wiley &Sons, Current Protocols in Molecular Biology,vol. 1,
`1999,
`Judge et al, Nature Biotechnology, vol. 23, No. 4, pp. 457-462, Apr.
`2005.
`Kalota et al. “2'-deoxy-2'-fluoro-beta-D-arabinonucleic acid (2'F-
`ANA) modified oligonucleotides (On) effect highly efficient, and
`persistent, gene silencing. ’Nucleic Acids Res. Jan. 18, 2006;
`34(2):451-61. Print 2006.
`Karberg, Mach doch mal das Gen aus, Die Zeit, No. 41, May 10,
`2006.
`Kitabwalla, M.et al. “RNA-Interference—A New Weapon Against
`HIV and Beyond”, N. Engl. J. Med. vol. 347, No. 17, pp. 1364-
`1367, Oct. 24, 2002.
`Klippel, A. et al. “The Interaction of Small Domains between the
`Subunits of Phosphatidylinositol 3-Kinase Determines Enzyme
`Activity”, Molecular and Cellular Biology, Apr. 1994, pp. 2675-
`2685, vol. 14, No. 4.
`Koller, E. et al. “Competition for RISC binding predicts in vitro
`potency of siRNA”, Nucleic Acids Research, 2006, pp. 4467-4476,
`vol. 34, No. 16.
`interfering RNAs containing full 2'-0-
`Kraynack et al.,“Small
`methylribonucleotidemodified sense strands display Argonaute2/
`eIF2C2-dependentactivity.” RNA. Jan. 2006;12(1 ):163-76.
`Kurreck, “Improvement through novel chemical modifications;”
`Eur. J. Biochem, 270, 1628-1644 (2003).
`Layzer, J. M.et al. “In vivo activity of nuclease-resistant siRNAs”,
`RNA,2004, pp. 766-771,vol. 10.
`Leenders, F. et al. “PKN3 is required for malignant prostate cell
`growth downstream of activated PI 3-kinase”, The EMBO Journal,
`2004, pp. 3303-3313, vol. 23, No. 16.
`Letter accompanying subsequently filed items filed in EPO Patent
`No. 1 527 176 (EP 03784183.0) dated Jul. 26, 2010, pp. 1-69.
`Li et al., Dev. Biology, vol. 210, 1999, p. 238, Abstr. 346.
`Lima, W.F. et al. “Structural Requirements at the Catalytic Site of
`the Heteroduplex Substrate for Human RNase H1 Catalysis”, The
`Journal of Biological Chemistry, Aug. 27, 2004, pp. 36317-36326,
`vol. 279, No. 35.
`Lipinski et al., Experimental and Computational Approaches to
`Estimate Solubility and Permeability in Drug Discovery and. Devel-
`opment Settings, Adv. Drug Delivery Reviews vol. 23, pp. 3-25,
`1997.
`
`
`
`Lubini, P. et al. “Stabilizing effects of the RNA 2'-substituent:
`crystal structure of an oligodeoxynucleotide duplex containing 2'-0-
`methylated adenosines”, Chemistry & Biology, Sep. 1994, pp.
`39-45, vol. 1.
`M. Monoharan;“2'-Carbohydrate modifications in antisense oligo-
`nucleotide therapy ... ;” Biochimica et Biophysica Acta; 1999, pp.
`117-130.
`Madhur Kumar,et al., Antisense RNA: Function and Fate of Duplex
`RNAin Cells of Higher Eukaryotes, Microbiology and Molecular
`Biology Reviews, Dec. 1998, pp. 1415-1434.
`Mahato et al. “Modulation of Gene Expression by Antisense and.
`antigene oligodeoxynucleotides and small interfering RNA”, Expert
`Opin. De/iv., 2005, pp. 3-28, vol. 2, No. 1.
`Majumdar, A.et al., Targeted Gene Knockout Medicated by Triple
`Helix Forming Oligonucleotides, Nature Genetics, vol. 20, Oct.
`1998, pp. 212-214.
`Mancheet al., Mol. Cell, Biol., vol. 12, No. 11, p. 5238-5248, Nov.
`1992.
`Manoharan, M. “RNAinterference and chemically modified. small
`interfering RNAs”, Current Opinion in Chemical Biology, 2004, pp.
`570-579, vol. 8.
`Manoharan, M.(Dec. 10, 1999). “2'-carbohydrate modifications in
`antisense oligonucleotide therapy:
`importance of conformation,
`configuration
`and
`conjugation,” Biochim Biophys Acta.
`1489(1):117-30.
`Maria Sternbergeret al., “GeneBlocs Are Powerful Tools to Study
`and Delineate A15 Signal Transduction Processes That Regulate
`Cell Growth and Transformation”, Antisense & Nucleic Acid Druq
`Development, 2002, pp. 131-143, vol. 12.
`Mark D. Pegram, et al., Phase II Study of Receptor-Enhanced.
`Chemosensitivity Using Recombinant Humanized Anti-p18S5her2/
`NEU Monoclonal Antibody Plus Cisplatin in Patients With HER2/
`neu-Overexpressing Metastatic Breast Cancer Refractory to Che-
`motherapy Treatment. Journal of Clinical Oncology, vol. 16, No. 8
`Aug. 1998: pp. 2659-2671.
`Martinez et al., Cell, vol. 110, pp. 563-574. Jun. 9, 2002.
`Martinez,J. et al. “RISC is a 5' phosphomonoester-producing RNA
`endonuclease”, Genes & Development, 2004, pp. 975-980, vol. 18.
`Martinez, J. et al. “Single-Stranded Antisense siRNAs Guide Target
`RNACleavage in RNAi”, Cell, Sep. 6, 2002, pp. 563-574, vol. 110.
`Mary K. Montgomery et al., “RNA as a Target of Double-Stranded.
`RNA-Mediated Genetic Interference in Caenorhabditis elegans”,
`Proceedings of the National Academy of Sciences of the United.
`States of America, Dec. 22, 1998, pp. 15502-15507, vol. 95, No. 26.
`Mary K. Montgomery,et al., Double-stranded RNA as a Mediator
`in Sequence-Specific Genetic Silencing and Co-Suppression, TIG,
`vol. 14 No. 7, pp. 255-256 and 256, Jul. 1998.
`McCaffrey, AP et al., Nature (2000), vol. 418, pp. 38-39.
`Michael T. McManus,et al. Gene Silencing in Mammals by Small
`Interfering RNAs, Center for Cancer Research Massachusetts, vol.
`3, pp. 737-750,Oct. 2002.
`Michael Y. X. Ma,
`et al., Design and Synthesis of RNA
`Miniduplexes via a Synthetic Linker Approach, Biochemistry, vol.
`32, No. 7, 1993, pp. 1751-1758.
`Mohammad B. Bahramian. et al., Transcriptional and Post-
`transcriptional Silencing of Rodent 01 (1) collagen by a Homolo-
`gous Transcriptionally Self-Silenced Transgene, R125 Molecular
`and Cellular Biology, Jan. 1999, vol. 19, No. 1. pp. 274-283.
`Morrissey et al. “Activity of stabilized short interfering RNA in a
`mouse model of hepatitis B virus replication.” Hepatology. Jun.
`2005;41(6):1349-56.
`Morrissey, D. V. et al. “Chemical Modification of Synthetic
`siRNA”, Pharmaceutical Discovery, May 13, 2005.
`Napoli, et al., Introduction of a Chimeric Chalcone Synthase Gene
`into Petunia Results in Reversible Co-Suppression of Homologous
`Genes in trans, The Plant Cell, vol. 2, pp. 279-289, Apr. 1990.
`Newsof the Week, Science, Candidate Gene Silencers Found,Fetal
`Cells Help Parkinson’s Patients, Science, vol. 286, p. 886, Dec.
`1999.
`Ngoet al., PNAS, vol. 95, Dec. 1998, p. 14687.
`Nikiforov,
`T.
`T.
`et
`al., Oligodeoxynucleotides Containing
`4-Thiothymidine and 6-Thiodeoxyguanosine as Affinity Labels for
`
`

`

`US 9,758,784 B1
`Page 5
`
`(56)
`
`References Cited
`OTHER PUBLICATIONS
`
`the Eco RV Restriction Endo nuclease and Modification Methylase.
`Nucleic Acids Research, 1992, vol. 20, pp. 1209-1214.
`Notice of Opposition to a European Patent dated Oct. 4, 2007
`against EPO Patent No. 1 527 176 (EP Patent Application No. 03
`784 183.0), Opponent Alnylam Pharmaceuticals, Inc., pp. 1-27.
`Notice of Opposition to a European Patent dated Oct. 4, 2007
`against EPO Patent No. 1527176 (EP Patent Application No. 03 784
`183.0), Opponent Dr. Martin Grund, pp. 1-16.
`Notice of Opposition to a European Patent dated Oct. 4, 2007
`against EPO Patent No. 1527176 (EP Patent Application No. 03 784
`183.0), Opponent Sirna Therapeutics, Inc., Inc., pp. 1-22.
`Oates, et al., Too Much Interference: Injection of Double-Stranded
`RNAHas Nonspecific Effects in the Zebrafish Embryo, Develop-
`mental Biology, Aug. 2000, pp. 20-28, vol. 224, Issue 1.
`Oliveira, S. et al. “Targeted Delivery of siRNA”, Journal of Bio-
`medicine and. Biotechnology, 2006, pp. 1-9, vol. 2006.
`Opposition filed on behalf ofAlcon Laboratories, Inc. In EPO Patent
`No. 1 527 176 (EP Patent Application No. 03 784 183.0) dated Sep.
`26, 2007, pp. 1-21.
`Orum,H. et al. Locked nucleic acids: A promising molecular family
`for gene-function analysis and antisense drug developmene Current
`Opinion in Molecular Therapeutics, 2001, pp. 239-243, vol. 3, No.
`3.
`P. Dan Cook, “Medicinal Chemistry of Antisense Oligoucleotides”;
`(ed. Crroke, S.T.), pp. 29-56 Marcel Dekker, NY 2001.
`Paddison,et al., Stable suppression of gene expression by RNAiin
`mammalian cells; PNAS, 99(3); pp. 1443-1448; (2002).
`Pancoska,P. et al. “Efficient RNA interference depends on global
`context of the target sequence: quantitative analysis of silencing
`efficiency using Eulerian graph representation of siRNA”, Nucleic
`Acids Research, 2004, pp. 1469-1479, vol. 32, No. 4.
`Park, et al., “Prevention of HIV-1 infection in human peripheral
`blood mononuclear cells by specific RNA interference;” Nucleic
`Acids Res., vol. 30, No. 22, pp. 4830-4835; (2002).
`Parrish, S. et al. “Functional Anatomy of a dsRNATrigger: Differ-
`ential Requirement for the Two Trigger Strands in RNA Interfer-
`ence”, Molecular Cell, Nov. 2000, pp. 1077-1087, vol. 6.
`Patel, D. J. et al. “Structural Biology of RNA Silencing and. Its
`Functional Implications”, Cold Spring Harbor Symposia on Quan-
`titative Biology, 2006, pp. 81-93, vol. LXXI.
`Patentee’s “Statement of Grounds of Appeal” against EP 1144623,
`Feb. 5, 2007, pp. 1-38.
`Patrick J. Paddison, et al., Short Hairpin RNAs (shRNAs) Induce
`Sequence-Specific Silencing in Mammalian Cells, Genes & Devel-
`opment vol. 16, pp. 948-958, 2002.
`Peek, A. S. et al. “Design of Active Small Interfering RNAs”,
`Current Opinion in Molecular Therapeutics, 2007, pp. 110-118, vol.
`9, No. 2.
`Pei, Y. et al. “On the Art of Identifying Effective and Specific
`siRNAs”, Nature Methods, Sep. 2006, pp. 670-676, vol. 3, No. 9.
`Perler, Nucl. Acids Res., vol. 30, No. 1, pp. 383-384, 2002.
`Peter M. Waterhouseet al., “Gene silencing as an adaptive defense
`against viruses”, Nature, Jun. 14, 2001, pp. 834-842, vol. 411.
`Peter M. Waterhouse, et al., Virus resistance and genesilencing in
`plants can be induced by simultaneous expression of sense and
`antisense RNA, Communicated by W. James Peacock, Common-
`wealth Scientific and Industrial Research Organization, Canberra,
`Australia, Aug. 17, 1998, vol. 95, pp. 13959-13964.
`Philip D. Zamore, et al., RNAi: Double-Stranded RNA Directs the
`ATP-Dependent Cleavage of mRNAat 21 to 23 Nucleotide Inter-
`vals, Cell, vol. 101, pp. 25-33, Mar. 31, 2000.
`Phillip A Sharp, RNAi and Double-strand RNA, Genes & Devel-
`opment, vol. 13, pp. 139-141, Cold Spring Harbor Laboratory Press,
`1999,
`Phillip A, Sharp, “RNA interference-2001”, Genes & Development,
`2001, pp. 485-490, vol. 15.
`Pierre G. Milhaud,et al., Free and Liposome-encapsulated. Double-
`Stranded RNAsas Inducersof Interferon, Interleukin6, and Cellular
`Toxicity, Journal of Interferon Research vol. 11, pp. 261-265,1991.
`
`Potera, C. “Antisense- down, but not out”, Nature Biotechnology,
`May 2007, pp. 497-499, vol. 25, No. 5.
`Poui Nielsen, et al., A Novel Class of Conformationally Restricted.
`Oligonucleotide Analogues: Synthesis of 2',3'-Bridged Monomers
`and RNA-Selective Hybridisation, Chern. Commun., 1997, pp.
`825-826.
`Priority Document of 9927444.1, Cancer Res. Camp. Technol. Ltd.
`Inhibiting Gene Expression, Publ. Nov. 19, 1999, Issued Nov. 22,
`2000.
`Priority Document of U.S. Appl. No. 60/117,635, Double-Stranded.
`RNABlocks Specific Gene Expression in Multicellular Settings in
`in Vivo and in Vitro, Mar. 14, 2000.
`Priority Document of U.S. Appl. No. 60/130,377, Methods and.
`Compositions for Inhibiting the Function of Polynucleotide, Issued.
`Jun. 6, 2000.
`R. Kreutzer, et al., Specific Inhibition of Viral Gene Expression by
`Double-Stranded RNA in vitro, Nature 391, p. 806, 1998.
`R. Schlingenslepen et al., Antisense- From Technology to Therapy,
`Ex L 1 BRIS [ROCHE], 1997, vol. 6, pp. 30-58.
`Rana, T. M. “Illuminating the silence: understanding the structure
`and function of small RNAs”, Molecular Cell Biology, Jan. 2007,
`pp. 23-36, vol. 8.
`Rand, T. A. et al. “Argonaute2 Cleaves the Anti-Guide Strand of
`siRNA during RISC Activation”, Cell, Nov. 18, 2005, pp. 621-629,
`vol. 123.
`Ravinderjit S. Braich, et al., Regiospecific Solid-Phase Synthesis of
`Branched Oligonucleotides. Effect ofVicinal 2',5"(or 2',3'-) and.
`3',5"Phosphodiester Linkages on the Formation of Hairepin DNA,
`Bioconjugate Chern., 1997, vol. 8, pp. 370-377.
`Reiko Iwase et al., Gene Regulation by Decoy Approach (1):
`Synthesis and Properties of Photo-crosslinked Oligonucleotides,
`Nucleic Acids Symposium Series, 1997, No. 37, pp. 203-204.
`Robert Barstead, “Genome-wide RNAi”, Current Opinion in
`Chemical Biology, 2001, pp. 63-66, vol. 5.
`Rosalind C. lee, et al., The C. Elegans Heterochronic Gene Lin-4
`Encodes Small RNAs with Antisense Complementarity to Lin-14,
`Cell, vol. 75, pp. 843-854, Dec. 3, 1993.
`Roseet al. “Functionalpolarity is introduced by Dicer processing of
`short substrate RNAs” Nucleic Acids Research, 2005, pp. 4140-
`4156, vol. 33, No. 13.
`Rossi, J. J. “A Cholesterol connection in RNAi”, Nature, Nov. 11,
`2004, pp. 155-156, vol. 432.
`Rueyling Lin and Leon Avery, Policing Rogue Genes, Nature, vol.
`402, pp. 128-129, Nov. 11, 1999.
`S. Blair Hedges, Nature Reviews, Genetics (2002), vol. 3, pp.
`838-849.
`Sant El, A. et al. “RNA interference in the mouse vascular
`endothelium by systemic administration of siRNA-lipoplexes for
`cancer therapy”, Gene Therapy, 2006, pp. 1360-1370, vol. 13.
`Santel, A. “Get the balance right: Mitofusins roles in health and
`disease”, Biochimica et Biophysica Acta, 2006, pp. 490-499, vol.
`1763.
`Santel, A. et al. “A novel siRNA-lipoplex technology for RNA
`interference in the mouse vascular endothelium”, Gene Therapy,
`2006, pp. 1222-1234, vol. 13.
`Sayda M. Elbashiret al., “Duplexes of 21-nucleotide RNAs mediate
`RNAinterference in cultured mammalian cells”, Nature, May 24,
`2001, pp. 494-498, vol. 411.
`Sayda M. Elbashir, et al, Analysis of Gene Function in Somatic
`Mammalian Cells Using Small Interfering RNAs, Methods,vol. 26,
`2002, pp. 199-213.
`Sayda M. Elbashir, et al., Functional Anatomy of siRNAs for
`Mediating Efficient RNAi
`in Drosophila melanogaster embryo
`Lysate, The EMBO Journal vol. 20, No. 23, pp. 6877-6888, 2001.
`Scherer, L. J. et al. “Approaches for the sequence-specific knock-
`down of mRNA”, Nature Biotechnology, Dec. 2003, pp. 1457-1465,
`vol. 21, No. 12.
`Schwarz, D. S. Evidence that siRNAs Function as Guides, Not
`Primers, in the Drosophila and Human RNAi